NASDAQ:BGNE

BeiGene Stock Forecast, Price & News

$311.89

-0.82 (-0.26 %)

(As of 07/29/2021 03:26 PM ET)

Add

Compare

Today's Range

$300.83

▼

$314.70

50-Day Range

$269.25

▼

$363.34

52-Week Range

$204.17

▼

$388.97

Volume10,026 shs

Average Volume261,656 shs

Market Capitalization$28.81 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.86

30 days | 90 days | 365 days | Advanced Chart

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

About BeiGene

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.

Why BeiGene Stock Soared Today - Motley Fool
July 28, 2021 | fool.com

BeiGene (NASDAQ:BGNE) Trading 7.3% Higher
July 28, 2021 | americanbankingnews.com

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 34% Undervaluation? - Yahoo Finance
July 27, 2021 | finance.yahoo.com

BeiGene (NASDAQ:BGNE) Shares Gap Down to $274.63
July 27, 2021 | americanbankingnews.com

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 34% Undervaluation?
July 27, 2021 | finance.yahoo.com

BeiGene (NASDAQ:BGNE) Sees Strong Trading Volume
July 26, 2021 | americanbankingnews.com

RSI Alert: BeiGene (BGNE) Now Oversold - Nasdaq
July 26, 2021 | nasdaq.com

BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma - Business Wire
July 26, 2021 | businesswire.com

Leap Therapeutics to Present at the ESMO 2021 Virtual Congress - Markets Insider
July 26, 2021 | markets.businessinsider.com

Health Canada approves BeiGene's Brukinsa for mantle cell lymphoma - Seeking Alpha
July 26, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BGNE
Previous Symbol
CUSIPN/A
CIK1651308
Webwww.beigene.com
Phone1-345-949-4123
Employees5,300
Year Founded2010

Sales & Book Value

Annual Sales$308.87 million
Price / Sales93.28
Cash FlowN/A
Price / Cash FlowN/A
Book Value$42.43 per share
Price / Book7.35

Profitability

EPS (Most Recent Fiscal Year)($19.13)
Net Income$-1,596,910,000.00
Net Margins-135.24%
Return on Equity-31.71%
Return on Assets-22.34%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares92,381,000
Market Cap$28.81 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.50 out of 5 stars

Medical Sector

950th out of 2,214 stocks

Pharmaceutical Preparations Industry

457th out of 869 stocks

2.2 Analyst's Opinion

Consensus Rating
BeiGene has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 6 buy ratings, 1 hold rating, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $347.00, BeiGene has a forecasted upside of 11.2% from its current price of $312.17.
Amount of Analyst Coverage
BeiGene has only been the subject of 2 research reports in the past 90 days.

3.6 Community Rank

Outperform Votes
BeiGene has received 499 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BeiGene has received 198 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BeiGene has received 71.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BeiGene and other stocks. Vote “Outperform” if you believe BGNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BeiGene does not currently pay a dividend.
Dividend Growth
BeiGene does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,530,110.00 in company stock.
Percentage Held by Insiders
Only 8.90% of the stock of BeiGene is held by insiders.
Percentage Held by Institutions
61.28% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for BeiGene are expected to decrease in the coming year, from ($10.65) to ($12.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BeiGene is -22.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BeiGene is -22.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BeiGene has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

BeiGene (NASDAQ:BGNE) Frequently Asked Questions

Is BeiGene a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BeiGene stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BGNE, but not buy additional shares or sell existing shares.
View analyst ratings for BeiGene or view top-rated stocks.

What stocks does MarketBeat like better than BeiGene?

Wall Street analysts have given BeiGene a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeiGene wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BeiGene's next earnings date?

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BeiGene.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings data on Friday, May, 7th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.90) by $2.59. The firm earned $605.87 million during the quarter, compared to analyst estimates of $103.90 million. BeiGene had a negative trailing twelve-month return on equity of 31.71% and a negative net margin of 135.24%.
View BeiGene's earnings history.

How has BeiGene's stock price been impacted by Coronavirus (COVID-19)?

BeiGene's stock was trading at $145.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BGNE shares have increased by 113.7% and is now trading at $311.38.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BGNE?

9 Wall Street analysts have issued 12 month price objectives for BeiGene's stock. Their forecasts range from $190.00 to $429.00. On average, they expect BeiGene's stock price to reach $347.00 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts' price targets for BeiGene or view top-rated stocks among Wall Street analysts.

Who are BeiGene's key executives?

BeiGene's management team includes the following people:

Mr. John V. Oyler, Co-Founder, Exec. Chairman & CEO (Age 53, Pay $1.41M) (LinkedIn Profile)
Dr. Xiaobin Wu Ph.D., Pres, COO & GM of China (Age 58, Pay $1.23M)
Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Committee & Non-Exec. Director (Age 58, Pay $4.25M)
Dr. Heng Liang, CFO & Chief Strategy Officer (Age 58, Pay $760.67k)
Dr. Edna Huang M.D., Chief Medical Officer of Hematology (Age 48, Pay $749.55k)
Mr. Daniel Maller, VP of Fin. & Accounting
Mr. Michael Garvey, Global Head of Technical Operations (Age 48)
Mr. Craig West CFA, Sr. Director of Investor Relations
Mr. Scott Samuels, Sr. VP & Gen. Counsel
Ms. Diana Lee Francis, VP and Global Head of Quality & Regulatory Compliance

What is John V. Oyler's approval rating as BeiGene's CEO?

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

Who are some of BeiGene's key competitors?

Some companies that are related to BeiGene include GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Astellas Pharma (ALPMY), Genmab A/S (GMAB), Shiseido (SSDOY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF) and Royalty Pharma (RPRX).
View all of BGNE's competitors.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

How do I buy shares of BeiGene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $311.38.

How much money does BeiGene make?

BeiGene has a market capitalization of $28.77 billion and generates $308.87 million in revenue each year. The company earns $-1,596,910,000.00 in net income (profit) each year or ($19.13) on an earnings per share basis.

How many employees does BeiGene have?

BeiGene employs 5,300 workers across the globe.

When was BeiGene founded?

BeiGene was founded in 2010.

What is BeiGene's official website?

The official website for BeiGene is www.beigene.com.

Where are BeiGene's headquarters?

BeiGene is headquartered at 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here